https://files.reportify.cc/media/production/ Exhibit 99.1 EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 – Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing expected in Q1 2026 – – Presenting at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13 ...